Is Inovio's stock a top COVID-19 play? While Inovio does have a strong track record of hauling in grant money for its experimental vaccines in general, the real needle-moving event with this biotech stock will no doubt be the upcoming late-stage readout for the company's lead product candidate VGX-3100. In short, investors probably shouldn't buy this stock solely for its tie-in to the pandemic. INO-4800, after all, is only a small piece of the company's overall value proposition.